223 related articles for article (PubMed ID: 21559450)
1. Preclinical models for neuroblastoma: establishing a baseline for treatment.
Teitz T; Stanke JJ; Federico S; Bradley CL; Brennan R; Zhang J; Johnson MD; Sedlacik J; Inoue M; Zhang ZM; Frase S; Rehg JE; Hillenbrand CM; Finkelstein D; Calabrese C; Dyer MA; Lahti JM
PLoS One; 2011 Apr; 6(4):e19133. PubMed ID: 21559450
[TBL] [Abstract][Full Text] [Related]
2.
Yogev O; Almeida GS; Barker KT; George SL; Kwok C; Campbell J; Zarowiecki M; Kleftogiannis D; Smith LM; Hallsworth A; Berry P; Möcklinghoff T; Webber HT; Danielson LS; Buttery B; Calton EA; da Costa BM; Poon E; Jamin Y; Lise S; Veal GJ; Sebire N; Robinson SP; Anderson J; Chesler L
Cancer Res; 2019 Oct; 79(20):5382-5393. PubMed ID: 31405846
[TBL] [Abstract][Full Text] [Related]
3. miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.
Terrile M; Bryan K; Vaughan L; Hallsworth A; Webber H; Chesler L; Stallings RL
PLoS One; 2011; 6(12):e28356. PubMed ID: 22164278
[TBL] [Abstract][Full Text] [Related]
4. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.
Althoff K; Beckers A; Bell E; Nortmeyer M; Thor T; Sprüssel A; Lindner S; De Preter K; Florin A; Heukamp LC; Klein-Hitpass L; Astrahantseff K; Kumps C; Speleman F; Eggert A; Westermann F; Schramm A; Schulte JH
Oncogene; 2015 Jun; 34(26):3357-68. PubMed ID: 25174395
[TBL] [Abstract][Full Text] [Related]
5. Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.
Evageliou NF; Haber M; Vu A; Laetsch TW; Murray J; Gamble LD; Cheng NC; Liu K; Reese M; Corrigan KA; Ziegler DS; Webber H; Hayes CS; Pawel B; Marshall GM; Zhao H; Gilmour SK; Norris MD; Hogarty MD
Clin Cancer Res; 2016 Sep; 22(17):4391-404. PubMed ID: 27012811
[TBL] [Abstract][Full Text] [Related]
6. Zebrafish as a Neuroblastoma Model: Progress Made, Promise for the Future.
Li S; Yeo KS; Levee TM; Howe CJ; Her ZP; Zhu S
Cells; 2021 Mar; 10(3):. PubMed ID: 33800887
[TBL] [Abstract][Full Text] [Related]
7. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M
Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152
[TBL] [Abstract][Full Text] [Related]
8. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
[TBL] [Abstract][Full Text] [Related]
9. Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.
Chayka O; Corvetta D; Dews M; Caccamo AE; Piotrowska I; Santilli G; Gibson S; Sebire NJ; Himoudi N; Hogarty MD; Anderson J; Bettuzzi S; Thomas-Tikhonenko A; Sala A
J Natl Cancer Inst; 2009 May; 101(9):663-77. PubMed ID: 19401549
[TBL] [Abstract][Full Text] [Related]
10. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
Zhong ZY; Shi BJ; Zhou H; Wang WB
J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
[TBL] [Abstract][Full Text] [Related]
11. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
12. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
13. Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis.
Teitz T; Inoue M; Valentine MB; Zhu K; Rehg JE; Zhao W; Finkelstein D; Wang YD; Johnson MD; Calabrese C; Rubinstein M; Hakem R; Weiss WA; Lahti JM
Cancer Res; 2013 Jul; 73(13):4086-97. PubMed ID: 23536557
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of a human orthotopic neuroblastoma xenograft.
Stewart E; Shelat A; Bradley C; Chen X; Federico S; Thiagarajan S; Shirinifard A; Bahrami A; Pappo A; Qu C; Finkelstein D; Sablauer A; Dyer MA
Dev Biol; 2015 Nov; 407(2):344-55. PubMed ID: 25863122
[TBL] [Abstract][Full Text] [Related]
15. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.
Rasmuson A; Segerström L; Nethander M; Finnman J; Elfman LH; Javanmardi N; Nilsson S; Johnsen JI; Martinsson T; Kogner P
PLoS One; 2012; 7(12):e51297. PubMed ID: 23284678
[TBL] [Abstract][Full Text] [Related]
16. Immune characterization of pre-clinical murine models of neuroblastoma.
Webb ER; Lanati S; Wareham C; Easton A; Dunn SN; Inzhelevskaya T; Sadler FM; James S; Ashton-Key M; Cragg MS; Beers SA; Gray JC
Sci Rep; 2020 Oct; 10(1):16695. PubMed ID: 33028899
[TBL] [Abstract][Full Text] [Related]
17. High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery.
Stauffer JK; Orentas RJ; Lincoln E; Khan T; Salcedo R; Hixon JA; Back TC; Wei JS; Patidar R; Song Y; Hurd L; Tsokos M; Lai EW; Eisenhofer G; Weiss W; Khan J; Wigginton JM
Cancer Invest; 2012 Jun; 30(5):343-63. PubMed ID: 22571338
[TBL] [Abstract][Full Text] [Related]
18. Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse.
Ferrandis E; Da Silva J; Riou G; Bénard I
Cancer Res; 1994 Apr; 54(8):2256-61. PubMed ID: 8174136
[TBL] [Abstract][Full Text] [Related]
19. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
[TBL] [Abstract][Full Text] [Related]
20. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.
Waldeck K; Cullinane C; Ardley K; Shortt J; Martin B; Tothill RW; Li J; Johnstone RW; McArthur GA; Hicks RJ; Wood PJ
Int J Cancer; 2016 Jul; 139(1):194-204. PubMed ID: 26914605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
